How might gut microbiota transplantation revolutionize the treatment of autoimmune diseases?

Recent research into the human microbiome has unveiled its critical role in various bodily functions, including immune system regulation. Autoimmune diseases, where the immune system mistakenly attacks healthy cells, affect millions worldwide and often require management rather than a cure. Gut microbiota transplantation (GMT), also known as fecal microbiota transplantation, involves transplanting gut bacteria from a healthy donor to a recipient to restore a balanced microbiome. This intriguing therapy could potentially reshape treatment strategies for autoimmune conditions by targeting the root cause rather than just symptoms. With emerging studies indicating promising results, how feasible is GMT as a mainstream treatment option, and what challenges must be addressed to optimize its efficacy and safety?